|52 Week High||175.91|
|52 Week Low||115.60|
|Mkt. Cap ($ Billion)||284.80|
*Delayed by 20 seconds.
|Name||Price ($)||Change%||M.Cap(Billion $)||TTM PE||TTM EPS||DY||52 wk high/low||Technical Rating|
|Eli Lilly||371.08||1.96||352.62||43.71||8.49||1.21||372.25/231.87||4.15||Very Bullish|
|Merck & Co||110.12||1.18||279.40||14.39||7.66||3.20||110.29/71.50||10.49||Very Bullish|
AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. AbbVie offers its products in various therapeutic categories, including Immunology products, which include Humira, Skyrizi and Rinvoq; Oncology products consists of Imbruvica and Venclexta; Aesthetics products include Botox Cosmetic, Juvederm Collection and other aesthetics; Neuroscience products, such as Botox Therapeutic, Vraylar, Duopa and Duodopa, and Ubrelvy; Eye care products consists of Lumigan, Alphagan and Restasis ; Women's health products incudes Lo Loestrin, Orilissa and other women's health; and Other key products, which includes Mavyret, Creon, Lupron, Linzess and Synthroid. The Company's products are sold worldwide directly to wholesalers, distributors, government agencies, health care facilities and independent retailers from AbbVie-owned distribution centers and public warehouses.